Step 1 topics → Hematology and Oncology → Von Willebrand Disease

Von Willebrand Disease

USMLE Step 1 trap: Misunderstands ristocetin as a direct platelet activator rather than a probe for vWF-GPIb interaction. Ristocetin induces platelet agglutination by mimicking vWF-GPIb binding; absent agglutination in vWD reflects deficient or dysfunctional vWF, not a platelet receptor defect.

Von Willebrand Disease (vWD) is the most common inherited bleeding disorder, caused by deficiency or dysfunction of von Willebrand factor (vWF). USMLE Step 1 makes this high-yield because vWF plays two completely separate roles — platelet adhesion via GPIb and Factor VIII carrier — and the exam exploits the most common management error: giving DDAVP to a patient with Type 2B vWD. In Type 2B, the mutant vWF has a gain-of-function that makes it spontaneously bind platelets too aggressively; releasing more of it with DDAVP causes pathological platelet clumping and worsens thrombocytopenia. The exam will test treatment by subtype, coagulation lab interpretation, and why the prolonged PTT in vWD reflects Factor VIII depletion rather than a primary intrinsic pathway defect.

The tricky part is that vWD straddles two worlds: it causes a platelet-type bleeding pattern (mucocutaneous bleeding, heavy periods, easy bruising — not hemarthroses like hemophilia), but it also prolongs the PTT because of secondary Factor VIII depletion. Students frequently misattribute the prolonged PTT to a primary clotting factor problem and miss the underlying vWF defect. USMLE Step 1 loves this ambiguity — you'll see a stem with a prolonged PTT and normal PT and have to decide whether you're looking at hemophilia A, hemophilia B, or vWD. The distinguishing move is the bleeding time (or PFA-100 closure time) and the ristocetin cofactor assay.

The other major exam trap is treatment by subtype. DDAVP works beautifully for Type 1 vWD by releasing stored vWF from endothelial cells, and it's the go-to answer most of the time. But it's explicitly contraindicated in Type 2B, where releasing more abnormal vWF makes things worse by causing pathological platelet clumping and worsening thrombocytopenia. Miss that distinction and you'll choose the wrong answer on a management question. Know all three subtypes — Type 1 (partial quantitative deficiency), Type 2 (qualitative defect, multiple variants), and Type 3 (near-complete absence) — and their lab patterns cold.

From real student decks
81%have cards covering this topic
57%have mature cards

Common misconceptions

Common mistake
Wrong: Ristocetin directly activates platelets through a receptor-mediated pathway.
Right: Ristocetin induces platelet agglutination by mimicking vWF-GPIb binding; absent agglutination in vWD reflects deficient or dysfunctional vWF, not a platelet receptor defect.
Ristocetin does not activate platelets through their own surface receptors — it has no physiological receptor on platelets. Instead, ristocetin is a tool that forces vWF to bind GPIb on platelets, mimicking what happens at a wound. In vWD, platelet aggregation fails in the ristocetin assay not because platelets are broken, but because vWF is absent or dysfunctional and can't bridge the gap. In Bernard-Soulier syndrome, by contrast, the vWF is fine but GPIb is missing — so that's how you separate the two with this test.
Common mistake
Wrong: DDAVP is safe and effective for all vWD subtypes.
Right: DDAVP is contraindicated in Type 2B vWD because releasing abnormal vWF worsens thrombocytopenia by causing spontaneous platelet clumping; Type 3 also requires vWF concentrate.
DDAVP works by triggering endothelial cells to release stored vWF from Weibel-Palade bodies, which is perfect for Type 1 where the released vWF is structurally normal. In Type 2B, the mutant vWF has a gain-of-function that makes it spontaneously bind platelets too aggressively — so releasing more of it causes pathological platelet clumping and drives platelet counts even lower. Giving DDAVP in Type 2B doesn't just fail to help; it actively makes the patient's thrombocytopenia worse, which is why it's a hard contraindication on the exam.
Common mistake
Wrong: The prolonged PTT in vWD reflects a primary intrinsic pathway defect.
Right: The prolonged PTT in vWD is secondary to reduced Factor VIII levels because vWF normally stabilizes Factor VIII in circulation; the primary defect is vWF deficiency.
The PTT measures the intrinsic coagulation pathway, and Factor VIII is part of that pathway — so a prolonged PTT in vWD looks like a primary Factor VIII problem at first glance. But the actual defect is upstream: vWF normally chaperones Factor VIII in the bloodstream, shielding it from proteolytic enzymes. When vWF is absent or deficient, Factor VIII gets chewed up prematurely, and its reduced level then prolongs the PTT as a downstream consequence. The primary defect is always vWF — the Factor VIII drop is secondary, and this distinction is exactly what separates vWD from hemophilia A on the exam.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Understand the two distinct functions of vWF — platelet adhesion to collagen via GPIb and protection of Factor VIII from proteolytic degradation — and how both are disrupted in vWD.
  2. Recognize the clinical presentation of vWD: mucocutaneous bleeding pattern (epistaxis, menorrhagia, gingival bleeding), autosomal dominant inheritance in most subtypes, and distinguish it from hemophilia's hemarthroses and deep tissue hematomas.
  3. Interpret the coagulation lab profile of vWD: prolonged bleeding time and PTT with normal PT, and understand how ristocetin cofactor assay, vWF antigen level, and vWF activity together diagnose and subtype vWD.
  4. Select the correct treatment based on vWD subtype: DDAVP for Type 1, vWF concentrate for Type 3, and recognize that DDAVP is contraindicated in Type 2B because it worsens thrombocytopenia; also know to avoid NSAIDs and aspirin in all vWD patients.

Can you avoid these mistakes?

A 16-year-old girl with heavy menstrual bleeding has a prolonged PTT, normal PT, prolonged bleeding time, and reduced ristocetin cofactor activity. What is the diagnosis, and what lab would you order next to confirm the specific subtype?
You're about to give DDAVP to a patient with vWD. What subtype would make you stop and reach for vWF concentrate instead — and what would happen to the platelet count if you gave DDAVP anyway?
A patient with vWD is about to have a tooth extraction. The surgeon asks which pain medications are safe. What do you tell them, and why does it matter for bleeding risk specifically in this disease?
In the ristocetin cofactor assay, you add ristocetin to a patient's platelet-rich plasma and see no agglutination. Name two different diseases that could cause this result and explain how you would distinguish between them using one additional test.

Related topics

Coagulation Cascade and PT/PTT Interpretation Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →